Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Net Income towards Common Stockholders (2022 - 2025)

Historic Net Income towards Common Stockholders for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$26.7 million.

  • Zentalis Pharmaceuticals' Net Income towards Common Stockholders rose 3353.5% to -$26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.3 million, marking a year-over-year increase of 1678.82%. This contributed to the annual value of -$165.9 million for FY2024, which is 3998.98% up from last year.
  • As of Q3 2025, Zentalis Pharmaceuticals' Net Income towards Common Stockholders stood at -$26.7 million, which was up 3353.5% from -$26.9 million recorded in Q2 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' Net Income towards Common Stockholders peaked at $10.0 million during Q1 2024, and registered a low of -$99.0 million during Q2 2023.
  • Its 4-year average for Net Income towards Common Stockholders is -$51.0 million, with a median of -$52.1 million in 2022.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 11642.4% in 2024, then crashed by 58086.65% in 2025.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Net Income towards Common Stockholders stood at -$48.4 million in 2022, then fell by 26.17% to -$61.0 million in 2023, then increased by 22.24% to -$47.5 million in 2024, then soared by 43.78% to -$26.7 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$26.7 million for Q3 2025, versus -$26.9 million for Q2 2025 and -$48.3 million for Q1 2025.